Genomic Health does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own health or cancer should seek medical advice from a qualified healthcare professional.

Genomic Health is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Founded in 2000, Genomic Health pioneered the field of genomic cancer diagnostics with the bold vision of analyzing the biology of a patient’s tumor to improve the quality of treatment decisions and long term outcomes. By dedicating ourselves to the development of practice-changing genomic tests, we are leading the effort to eliminate the “one-size-fits-all” therapeutic approach to cancer that often results in either over- or under-treatment.

When we introduced our first product, the Oncotype DX breast cancer test, in 2004, not only did we address the need to identify the small percentage of patients with early-stage disease who will truly benefit from chemotherapy, we also established a new paradigm for the development of genomic-based diagnostic tests that empower physicians and patients to personalize and optimize treatment planning.

As the first step in developing tests that can answer critical questions about individual cancers, we conduct sophisticated studies to help us understand which patterns of gene expression within a tumor are linked to the likelihood of the cancer returning or spreading, or to a response to a specific cancer therapy. Each test is aimed at answering an important clinical question, such as:

Do I need chemotherapy? (invasive breast cancer)

Do I need additional treatment after surgery (DCIS breast cancer)

Do I need surgery? (early-stage prostate cancer)

Which therapy going forward may be the most effective for me? (late-stage prostate cancer)

Do I have aggressive cancer? (stage II/III colon cancer)

We then work with collaborators to carefully design and conduct multiple studies in large, relevant patient populations to validate each test from a clinical and analytical perspective. These studies generate reproducible data that is presented and published in peer-reviewed settings. We also conduct clinical utility studies that consistently demonstrate to physicians, patients, and payors that our tests are impacting treatment decisions, providing significant benefit from both a patient outcome and cost perspective.

The rigor of our approach has resulted in an unparalleled track record; we have achieved more than 155 peer-reviewed publications and conducted over 100 successful clinical studies in more than 65,000 breast, colon and prostate cancer patients. This growing body of scientific and clinical evidence has driven the success of our tests in making cancer care smarter and improving patient outcomes.

Our World Class Commercial Channel

We deliver over 400 Oncotype DX test results per day to more than 90 countries through our centralized clinical laboratory.